Metrion Biosciences (UK) is receiving €2.2M in funding for its project to develop phenotypic cardiac safety assays, that could make drug discovery cheaper and faster.
Metrion is a Contract Research Organization out of the Babraham Institute in Cambridge (one of the 10 hottest bioincubators in Europe). It provides screening services for drugs still in the discovery phase, especially characterising the drug’s interaction with cellular ion channels.
A project to develop novel Cardiac safety assays (for heart muscle) led by Metrion, has now been granted €2.2M in funding by the Eurostars programme.
Currently, indicators of a candidate’s risk of developing heart arrhythmia was by testing how the drug would interact with the patients potassium ion channels (e.g. hERG channel).
This is measured by the type of assay services Metrion provides,